Appearance of bone marrow lymphocytosis predicts an optimal response to imatinib therapy in patients with chronic myeloid leukemia

Leukemia. 2007 Nov;21(11):2363-8. doi: 10.1038/sj.leu.2404807. Epub 2007 Jun 14.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Benzamides
  • Bone Marrow / pathology*
  • Bone Marrow Cells / metabolism
  • Chromosome Banding
  • Female
  • Humans
  • Imatinib Mesylate
  • Immunophenotyping
  • Karyotyping
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology*
  • Lymphocytes / metabolism
  • Lymphocytosis / drug therapy*
  • Lymphocytosis / pathology*
  • Male
  • Middle Aged
  • Piperazines / therapeutic use*
  • Prognosis
  • Pyrimidines / therapeutic use*

Substances

  • Benzamides
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate